a b s t r a c t
Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardiovascular events, with assigned low density lipoprotein cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl and 115 mg/ dl, respectively. Overall, the highest proportion of patients meeting their LDL-C target was seen in the UAE and Kuwait (49.5%), while the lowest was seen in Germany (14.3%). The smallest median distance to target was documented in Canada (18.8 mg/dl), and the largest in the Baltics (42.1 mg/dl).
Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/dib Interpretation and discussion of this data can be found in the manuscript entitled "Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients" (Gitt et 
Value of the data
These data are gathered from a large, worldwide registry and insights are therefore applicable to physicians globally.
As data are stratified by individual country, target attainment within different national healthcare systems can be compared and potential improvements made based on the experience of more successful countries.
Data can be used as a basis from which to launch further studies investigating optimal treatment regimes for patients at risk of cardiovascular events, both globally and within individual countries. Table 1 displays the proportion of patients attaining risk based target LDL-C values in a global cohort, overall and divided by country and region of the world. Table 2 displays the median distance to risk based treatment targets in a global cohort, overall and divided by country and region of the world.
Data

Experimental design, materials and methods
The methodology for DYSIS (a cross-sectional, observational, multicenter registry) has been described elsewhere [1] . Briefly, statin-treated (mono/combination therapy) outpatients were consecutively enrolled at multiple centers located in 30 different countries worldwide. The study was approved by the relevant ethics committees and carried out in agreement with local laws.
Inclusion criteria were as follows: 1) provision of written informed consent, 2) availability of a fasting blood lipid profile taken within 6-12 months of study entry, at which time the participant had been on statin therapy for a minimum of 3 months 3) aged Z45 years and on statin therapy at time of inclusion 4) not participating in a clinical trial.
The 2011 ESC/EAS guidelines on treatment of dyslipidemia were used for stratification of patients into risk categories [2] . Patients considered at "very high risk" of cardiovascular events were those diagnosed with CHD, diabetes, chronic kidney disease, and/or peripheral artery disease, whereas those with markedly elevated single risk factors such as total cholesterol 4310 mg/dl or severe hypertension (SBP Z180 and/or DBPZ 110 mmHg) were determined to be "high-risk". All other patients were determined to be "not high-risk". LDL-C targets of 70 mg/dl, 100 mg/dl, and 115 mg/dl were assigned to very high-, high-and non-high-risk patients, respectively, in accordance with 2011 ESC/EAS guidelines.
Serum lipid levels were obtained from the most recent blood test for each patient, and data on lipid-lowering agents (statin type, dose, and other concomitant lipid-modifying therapies) that were being taken by the patient at that time were documented. Simvastatin was used as a reference to calculate the relative potency of other statins for comparison [3] . A central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany was used to collect and store the data.
The SAS © statistical package, Version 9.3 (SAS Institute, Cary, North Carolina, USA) was used for data analysis purposes. Data were processed and presented as percentages (n/N) or medians (IQR), all of which were based one the number of patients with data for a particular case available. Categorical a Corresponding LDL-C targets for very high-, high-and non-high-risk patients were o70 mg/dl, o100 mg/dl and 115 mg/dl, respectively. 
